Basic Information
RNALocate ID: | RLID:01002583 |
RNA Symbol: | hsa-miR-99a-3p |
Localization: | Mitochondrion |
RNA Information
RNA Name: | hsa-miR-99a* |
RNA ID: | miRBase:MIMAT0004511 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21637849 |
Tissue/Cell Line: | Skeletal muscle myoblasts |
Method: | ISH|qRT-PCR |
Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11003618 | Exosome | Plasma | 23663360 |
RLID-D:11000589 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001467 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-99a-3p | Oral squamous cell carcinoma | MNDR-E-MI-73000 |
MNDR | hsa-miR-99a-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-73001 |
MNDR | hsa-miR-99a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-73002 |
MNDR | hsa-miR-99a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-73003 |
MNDR | hsa-miR-99a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-73004 |
MNDR | hsa-miR-99a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-73005 |
MNDR | hsa-miR-99a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-73006 |
MNDR | hsa-miR-99a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-73007 |
MNDR | hsa-miR-99a-3p | Prostate cancer | MNDR-E-MI-73008 |
MNDR | hsa-miR-99a-3p | Alzheimer disease | MNDR-E-MI-73009 |
MNDR | hsa-miR-99a-3p | Lung cancer | MNDR-E-MI-73010 |
MNDR | hsa-miR-99a-3p | Parkinson disease | MNDR-E-MI-73011 |
MNDR | hsa-miR-99a-3p | Breast cancer | MNDR-E-MI-73012 |
MNDR | hsa-miR-99a-3p | Pancreatic cancer | MNDR-E-MI-73013 |
MNDR | hsa-miR-99a-3p | Melanoma | MNDR-E-MI-73014 |
MNDR | hsa-miR-99a-3p | Nephroblastoma | MNDR-E-MI-73015 |
MNDR | hsa-miR-99a-3p | Familial ovarian cancer | MNDR-E-MI-73016 |
MNDR | hsa-miR-99a-3p | Prostate adenocarcinoma | MNDR-E-MI-73017 |
MNDR | hsa-miR-99a-3p | Carcinoma ductal breast | MNDR-E-MI-73018 |
MNDR | hsa-miR-99a-3p | Glioblastoma | MNDR-E-MI-73019 |
MNDR | hsa-miR-99a-3p | Breast carcinoma | MNDR-E-MI-73020 |
MNDR | hsa-miR-99a-3p | Gastric adenocarcinoma | MNDR-E-MI-73021 |
MNDR | hsa-miR-99a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-73022 |
MNDR | hsa-miR-99a-3p | Lung squamous cell carcinoma | MNDR-E-MI-73023 |
MNDR | hsa-miR-99a-3p | Lung adenocarcinoma | MNDR-E-MI-73024 |
MNDR | hsa-miR-99a-3p | Ovarian carcinoma | MNDR-E-MI-73025 |
MNDR | hsa-miR-99a-3p | Bladder urothelial carcinoma | MNDR-E-MI-73026 |
MNDR | hsa-miR-99a-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-73027 |
MNDR | hsa-miR-99a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-73028 |
MNDR | hsa-miR-99a-3p | Renal clear cell carcinoma | MNDR-E-MI-73029 |
MNDR | hsa-miR-99a-3p | Cholangiocarcinoma | MNDR-E-MI-73030 |
MNDR | hsa-miR-99a-3p | Synovial sarcoma | MNDR-E-MI-73031 |
MNDR | hsa-miR-99a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-73032 |
MNDR | hsa-miR-99a-3p | Breast invasive carcinoma | MNDR-E-MI-73033 |
MNDR | hsa-miR-99a-3p | Hepatocellular carcinoma | MNDR-E-MI-73034 |
MNDR | hsa-miR-99a-3p | Familiar ovarian carcinoma | MNDR-E-MI-73035 |
MNDR | hsa-miR-99a-3p | Malignant pleural mesothelioma | MNDR-E-MI-73036 |
MNDR | hsa-miR-99a-3p | Colorectal cancer | MNDR-E-MI-73037 |
MNDR | hsa-miR-99a-3p | Nasopharynx carcinoma | MNDR-E-MI-73038 |
MNDR | hsa-miR-99a-3p | Nasopharyngeal cancer | MNDR-E-MI-73039 |
MNDR | hsa-miR-99a-3p | Breast cancer her3+ negative | MNDR-E-MI-73040 |
TOP